Risk of CNS relapse following pathological complete response to neoadjuvant chemotherapy in early breast cancer [0.03%]
Luciana de Moura Leite,Guilherme Rossato de Almeida,Monique Celeste Tavares et al.
Luciana de Moura Leite et al.
Purpose: Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) improves outcomes in breast cancer (BC); however it may not prevent brain metastases. We evaluated central nervous system (CNS) recurrence...
House value as an individual socioeconomic indicator for breast cancer survival and late-stage diagnosis: a population-based cohort study from Northern Ireland [0.03%]
Sarah M Baxter,Charlene M McShane,Stuart A McIntosh et al.
Sarah M Baxter et al.
Purpose: Socioeconomic inequalities in breast cancer survival persist in the UK. Area-based deprivation measures may underestimate socioeconomic effects by assigning average deprivation levels to all area inhabitants. Thi...
Correction to: A Canadian real‑world, multi‑center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2‑negative advanced breast cancer [0.03%]
Catherine Doyle,Ana Elisa Lohmann,Nayyer Iqbal et al.
Catherine Doyle et al.
Published Erratum
Breast cancer research and treatment. 2026 Mar 19;216(3):32. DOI:10.1007/s10549-026-07934-4 2026
Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study [0.03%]
Norikazu Masuda,Hiroyuki Yasojima,Hiroko Bando et al.
Norikazu Masuda et al.
Purpose: To investigate long-term outcomes for triple‑negative breast cancer (TNBC) patients enrolled in JBCRG-22. Methods: TNBC (cT1c...
Randomized Controlled Trial
Breast cancer research and treatment. 2026 Mar 19;216(3):31. DOI:10.1007/s10549-026-07917-5 2026
Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study [0.03%]
Matheus de Oliveira Andrade,Renata Colombo Bonadio,Agustina Ipiña et al.
Matheus de Oliveira Andrade et al.
Purpose: For early-stage triple-negative breast cancer (TNBC), the KEYNOTE-522 trial established neoadjuvant pembrolizumab plus chemotherapy (CT), followed by adjuvant pembrolizumab, as the standard of care. Nevertheless,...
Multicenter Study
Breast cancer research and treatment. 2026 Mar 18;216(3):27. DOI:10.1007/s10549-026-07938-0 2026
Omission of axillary surgery in early breast cancer with negative lymph nodes: a systematic review and meta-analysis of randomized clinical trials [0.03%]
Bárbara Bizzo Castelo,Luiz Gustavo Oliveira Brito,Renato Zocchio Torresan et al.
Bárbara Bizzo Castelo et al.
Purpose: To evaluate whether the omission of axillary surgery impacts clinical outcomes in patients with early-stage breast cancer and clinically negative lymph nodes. ...
ESR1 polymorphisms were associated with aromatase inhibitors induced musculoskeletal symptoms in breast cancer patients [0.03%]
Feng Jing,Lingyun Jiang,Yuling Cao et al.
Feng Jing et al.
Purpose: Aromatase Inhibitors Associated Musculoskeletal Symptoms (AIMSS) are common side effects among hormone receptor-positive breast cancer patients, significantly affecting patients' treatment adherence and quality o...
Comment on: "Prognostic performance of thymidine kinase 1 activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with CDK4/6 and aromatase inhibitors" [0.03%]
Sangameshwar Manikya,Varshini Vadhithala,Rajnish Kumar et al.
Sangameshwar Manikya et al.
Unlocking the predictive value of post-neoadjuvant immune biomarkers in breast cancer: neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII) [0.03%]
María Esperanza Guirao García,Pedro Marín Rodríguez,Carmen María Servet Pérez de Lema et al.
María Esperanza Guirao García et al.
Purpose: To evaluate the potential prognostic value of two peripheral immune biomarkers-neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII)-in breast cancer patients treated with neoadjuvant ...
Molecular imaging of tucatinib-induced cellular and TME changes in preclinical models of HER2 + breast cancer [0.03%]
用于HER2阳性乳腺癌前期模型中tucatinib诱导的细胞和TME变化的分子成像
Patrick N Song,Ameer Mansur,Carlos A Gallegos et al.
Patrick N Song et al.
Introduction: Tucatinib, a small molecule HER2 inhibitor, was approved in inoperable or metastatic HER2 + breast cancer. As many patients have tumors in challenging surgical locations, there is a need for imaging metrics ...